Mission and Values

MigVax was established as SPV by MIGAL, which granted MigVax an exclusive worldwide license to make, use and practice the vaccine technology for the development, manufacture, and commercialization of vaccine for viruses in humans, starting with the COVID-19.

 

The COVID-19 vaccine project initiated upon a inter-disciplinary research team successful development of a vaccine against Infectious Bronchitis Virus (IBV), an avian (poultry) Coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism.

 

Given the similarity, and following required genetic adjustments, the same vaccination concepts should apply. The inter-disciplinary research group is uniquely qualified to carry out this work. It carries several years of experience in vaccine development projects at MIGAL. 

About MigVax Ltd.

 
The Team

Management

David Zigdon                         Interim CEO

Prof. Itamar Shalit                SAB Clinical

Ori Ben-Herzel                      VP BizDev

Rivka Zaibel                           QA/RA Consultant

Roni Pinkus Ph.D.                  Production Consultant

Sigal Tal MD.                          VP Clinical & Regulatory

Ronald Ellis Ph.D.                  CTO

 

Einav Askenazi                      Project Manager

Research

Prof. Jacob Pitcovski            Virology and Poultry Vaccination

Ehud Shahar Ph.D.               Immunology

Chen Katz, Ph.D.                   Microbiology

Itai Bloch                               Computational Chemistry

Itamar Yadid, Ph.D.              Microbial Metabolic Pathways

 

Migal Galilee Research Institute Ltd, an internationally-recognized multi-disciplinary applied research institute located in Israel’s northern Galilee. Migal was established in 1979, and today is addressing the world’s most pressing challenges by research in biotechnology, computer sciences, plant science, precision agriculture and environmental sciences, and food, nutrition and health. Recognized as a powerhouse of applied research, for forty years MIGAL has cooperated closely with industry leaders, innovative startups, and technological accelerators. MIGALs' employees include 90 PhDs and 190 researchers distributed across 44 research groups, operating as an innovative research ecosystem that encourages collaboration across scientific, industrial, agricultural, academic and technological specialties.

 

Logo MIGAL - Copy.png
MIGAL grants its SPV MigVax exclusive worldwide license to use its vaccine technology
  • LinkedIn
  • Facebook
  • RSS

© 2020 by MigVax Ltd. All rights reserved.